Search
Inotersen
go.drugbank.com/drugs/DB14713ApprovedInvestigationalIt was FDA approved in October 2018. … Inotersen is a transthyretin-directed antisense oligonucleotide for the treatment of the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults.
Alectinib
go.drugbank.com/drugs/DB11363ApprovedInvestigationalApproved under accelerated approval in 2015, alectinib is indicated for use in patients who have progressed on or were not tolerant of crizotinib, which is associated with the development of resistance … Inhibition of ALK prevents phosphorylation and subsequent downstream activation of STAT3 and AKT resulting in reduced tumour cell viability.
Butalbital
go.drugbank.com/drugs/DB00241ApprovedIllicitButalbital, or 5-allyl-5-isobutylbarbituric acid, is a derivative of barbituric acid which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group. … [L10370] Butalbital‐containing analgesics can also produce a drug‐induced headache in addition to tolerance and dependence.
Synonyms: 5-allyl-5-(2'-methyl-n-propyl) barbituric acidConcizumab
go.drugbank.com/drugs/DB12820ApprovedInvestigational[L52043] Concizumab-mtci (Alhemo) was approved by the FDA in December 2024 for use in patients with hemophilia A or B with inhibitors. … [A264883,A264878] In patients with hemophilia A or B - characterized by deficiencies in clotting factors VIII or IX, respectively - the traditional treatment involves replacement of the missing clotting
Levamlodipine
go.drugbank.com/drugs/DB09237ApprovedInvestigational[A188940] Levamlodipine was granted FDA approval on 19 December 2019.[L10833] … [L10833] This medication was first marketed in Russia and India before being granted FDA approval.
Cidofovir
go.drugbank.com/drugs/DB00369ApprovedInvestigationalCidofovir is an injectable antiviral medication employed in the treatment of cytomegalovirus (CMV) retinitis in patients diagnosed with AIDS. … [FDA label] It was manufactured by _Gilead_ and initially approved by the FDA in 1996, but has since been discontinued.[L6223]
Abrocitinib
go.drugbank.com/drugs/DB14973ApprovedInvestigationalAbrocitinib is an oral small-molecule inhibitor of Janus kinase 1 (JAK1). … [A244549] Abrocitinib was approved by the European Commission on December 10, 2021, for the treatment of moderate-to-severe atopic dermatitis (AD) in adults who are candidates for systemic therapy.
Human cytomegalovirus immune globulin
go.drugbank.com/drugs/DB13886ApprovedInvestigationalThe seroprevalence of antibodies in adults ranges from 40-100 % with an inverse correlation to socioeconomic status. … During the span of an individual's life, the virus may reactivate, resulting in repeated shedding and spread of the virus.
Vorinostat
go.drugbank.com/drugs/DB02546ApprovedInvestigationalIt is the first in a new class of agents known as histone deacetylase inhibitors. … A recent study suggested that vorinostat also possesses some activity against recurrent glioblastoma multiforme, resulting in a median overall survival of 5.7 months (compared to 4 - 4.4 months in earlier
Spironolactone
go.drugbank.com/drugs/DB00421ApprovedInvestigational[A178135, A261025] Spironolactone was developed in 1957, marketed in 1959, and approved by the FDA on January 21, 1960.[A178243]